Table 1.
Characteristics of included and not included women living with HIV (WLWH) in Denmark from the Danish HIV Cohort Study (DHCS)
| WLWH included in the study | WLWH not included in the study | p-value | |
|---|---|---|---|
| Number of individuals | 334 (24.0) | 1,058 (76.0) | NA |
| Follow-up (years), median (IQR) | 11.3 (5.9-16.9) | 10.6 (5.5-15.9) | 0.097 |
| Follow-up time, total (person-years) | 3,853 | 11,183 | NA |
| Age at inclusion (years), median (IQR) | 42.5 (36.8-48.3) | 42.0 (35.5-48.2) | 0.22 |
| Race, n(%) | |||
| White | 141 (42.6) | 398 (39.5) | 0.041a |
| Asian | 44 (13.3) | 114 (11.3) | |
| Black | 143 (43.2) | 461 (45.7) | |
| Other | 3 (0.9) | 35 (3.5) | |
| (missing) | (3) | (50) | |
| Place of HIV transmission, n(%) | |||
| Denmark | 114 (37.8) | 326 (34.8) | 0.11 |
| Europe + US | 27 (8.9) | 77 (8.2) | |
| Africa | 128 (42.4) | 416 (44.4) | |
| Asia | 33 (10.9) | 101 (10.8) | |
| Other | 0 (0) | 17 (1.8) | |
| (missing) | (32) | (121) | |
| Mode of transmission, n(%) | |||
| Heterosexual | 294 (91.6) | 799 (83.6) | 0.0015 |
| IDU | 16 (5.0) | 106 (11.1) | |
| Other | 11 (3.4) | 51 (5.3) | |
| (missing) | (13) | (102) | |
| Age at sexual debut (years), | |||
| mean (range) | 17.3 (6–37) | -b | NA |
| Lifetime sexual partners, n(%) | |||
| < 5 | 99 (29.6) | -b | NA |
| 5–14 | 135 (40.4) | ||
| 15–25 | 45 (13.5) | ||
| > 25 | 53 (15.9) | ||
| Does not wish to respond | 2 (0.6) | ||
| (missing) | (0) | ||
| CD4 count at inclusion (cells/μL), n(%) | |||
| < 200 | 12 (3.9) | 79 (9.1) | 0.012 |
| 200–350 | 51 (16.5) | 138 (15.9) | |
| > 350 | 247 (79.7) | 650 (75.0) | |
| (missing) | (24) | (191) | |
| HAART at inclusion, n(%) | |||
| Yes | 317 (94.9) | 866 (81.8) | <0.0001 |
| No | 17 (5.1) | 192 (18.2) | |
| (missing) | (0) | (0) | |
| On HAART with | |||
| HIV RNA < 40 copies/mL, n(%) | |||
| Yes | 250 (83.6) | 576 (75.5) | 0.0042 |
| No | 49 (16.4) | 187 (24.5) | |
| (missing) | (18) | (103) | |
| Cervical cytology within the past 1 year, n(%)c | |||
| Yes | 124 (37.1) | 225 (21.3) | <0.0001 |
| No | 210 (62.9) | 833 (78.7) | |
| (missing) | (0) | (0) | |
| Cervical cytology within the past 3/5 years – depending on age for women age 23–65 years, n(%)d | |||
| Yes | 227 (67.7) | 429 (40.6) | <0.0001 |
| No | 96 (28.7) | 555 (52.5) | |
| Outside target age group | 11 (3.3) | 74 (7.0) | |
| (missing) | (0) | (0) | |
| Last cytology result, n(%) | |||
| Normal | 242 (72.5) | 513 (48.5) | <0.0001 |
| Abnormal | 9 (2.7) | 21 (2.0) | |
| No prior cytology obtained | 83 (24.9) | 524 (49.5) | |
| HPV vaccination prior to inclusion, n(%) | |||
| Yes (4-valent HPV vaccine) | 4 (1.2) | -b | NA |
| Yes (2-valent HPV vaccine) | 0 (0) | ||
| Yes (do not know name of vaccine) | 1 (0.3) | ||
| No | 329 (98.5) | ||
| (missing) | (0) | ||
IDU intravenous drug user, NA not applicable, HAART Highly active antiretroviral therapy, HPV Human papillomavirus
aThere was no difference in distribution of race between groups if the category “other” was removed from the “Race” variable (p = 0.45), bNo information available, cAs recommended in women living with HIV (we studied the past year + a 3-month grace period), dAs recommended in the general population, where women aged 23–49 years were invited for cervical cancer screening every third year and women aged 50–65 years every fifth year (we studied the past 3/5 years + a 3-month grace period)